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ABSTRACT
Objective: The Sorin Pericarbon Freedom (SPF) is a stentless valve made of pericardium clinically 
available in 1990. We report the clinical and hemodynamic performance of the SPF at 10 years. 
Methods: From April 2000 to December 2005, 85 patients with a mean age of 75 ± 6 years (range 57-86), 
underwent aortic valve replacement (AVR) with an SPF. Mean left ventricular ejection fraction was 58 ± 
10% (range 29-86%) and mean peak transvalvular gradient (PG) 86 ± 24 mm Hg. Clinical evaluation was 
performed at 3, 6, 12 months, and yearly thereafter.
Results: There were 2 operative deaths (2.4%). Follow-up ranged from 2 to 135 months (mean 78 ± 
32 months) and was 99% complete. There were 35 late deaths, 7 of which were valve-related, with 
an actuarial survival of 45 ± 8% at 10 years. Structural SPF deterioration occurred in 2 patients, with 
an actuarial freedom of 96 ± 3%. A total of 4 patients were re-operated, 2 because of structural de-
terioration, 1 because of endocarditis, and 1 because of sinotubular junction dilatation; freedom from 
reoperation was 93 ± 4% at 10 years. At last clinical control, 41 patients (89%) were in NYHA class I 
or II. Mean SPF effective orifice area varied from 1.55 ± 0.66 cm2 for size 21 mm to 2.33 ± 0.86 cm2 
for size 27 mm; PG varied from 19 ± 10 mm Hg for size 21 mm to 11 ± 6 mm Hg for size 27 mm. Left 
ventricular mass index decreased from 213 ± 51 gm/m2 to 157 ± 436 gm/m2 (p<0.001).
Conclusions: The SPF has demonstrated overall good results in terms of valve durability and freedom 
from valve-related complications up to 10 years, with excellent hemodynamic performance.
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INTRODUCTION
Stentless bioprostheses have proven to be a valid alterna-
tive to traditional stented tissue valves, particularly owing 
to their superior hemodynamic performance which allows 
an earlier and more complete regression of left ventricular 
hypertrophy and increased survival following aortic valve 
replacement (AVR) (1-4). Despite this, stentless valves have 
not gained worldwide acceptance mainly because the com-
plexity of implantation techniques; moreover, recent reports 
have indicated that the durability of some of the currently 
available models may be limited (5). To address the issue of 
ease of implantability and prolonged durability a new gen-
eration of stentless valves has been manufactured. Among 
these, there is the Sorin Pericarbon Freedom (SPF; Sorin 
Biomedica, Saluggia, Italy) a stentless valve made entirely 
of pericardium, which has been available for clinical use 
since 1990. After more than two decades, however, clini-
cal data on the performance of this device are extremely 
limited. The purpose of this report is to present a long-term 
clinical follow-up on the SPF in a series of patients under-
going AVR. 
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size that would fit the annulus was chosen. According to 
the preference of each surgeon, the SPF were implanted ei-
ther with interrupted 4/0 sutures of Ethibond (Ethicon Inc., 
St-Stevens-Woluwe, Belgium) or with 3 continuous sutures 
of 3/0 polypropylene to secure the inflow pericardial rim, af-
ter the valve had been inverted into the LV. The valve was 
then pulled out and the outflow pericardial rim was always 
MATERIALS AND METHODS
After obtaining approval from the Ethics Committee of both 
hospitals, a retrospective study was carried out on patients 
having AVR with an SPF at the departments of cardiac sur-
gery of the university hospitals of Verona and Pisa, Italy. 
A total of 85 patients, operated on from April 2000 to 
December 2005, form the basis of this report.
Clinical data
Preoperative clinical data are summarized in Table I. Preop-
erative mean functional class, according to the New York 
Heart Association (NYHA) classification, was 2.5 ± 0.7, peak 
transvalvular gradient (PG) was 86 ± 24 mm Hg, mean gradi-
ent (MG) 57 ± 14 mm Hg, aortic valve area 0.62 ± 0.20 cm2, 
indexed aortic valve area 0.38 ± 011 cm2/m2 (mean body 
surface area of 1.73 ± 0.16 m2), mean left ventricular (LV) 
ejection fraction was 58 ± 10% (range 29-86%), and mean 
LV mass index 213 ± 51 gm/m2. 
SPF characteristics
The SPF is a stentless bioprosthesis made of 2 sheets of 
bovine peiricardium sutured together with no fabric rein-
forcement. The pericardium is treated with glutaraldehyde 
and then submitted to a detoxification process with homo-
cysteic acid to neutralize the residues of unbound aldehyde 
groups left after the fixation process. The valve is then stored 
in a aldehyde-free solution without the need for rinsing prior 
to implant (6).
Surgical technique
All patients were operated through a standard sternotomic 
incision, with moderate systemic hypothermia. Antegrade 
cold blood cardioplegia was administered in the aortic root 
or into the coronary ostia in case of aortic valve incompe-
tence. Topical cooling with iced saline was used through-
out each procedure. Associated procedures such as distal 
coronary anastomoses in case of myocardial revascular-
ization were performed prior to AVR. The aortic valve was 
approached through a transverse aortotomy approximately 
2 to 3 cm above the coronary ostia. It was excised and 
the annulus was carefully debrided of calcium infiltrates, 
when needed, paying attention not to cause any annu-
lar disruption. The annulus was then sized and the largest 
TABLE I -  SUMMARY OF PATIENT CHARACTERISTICS AND 
STUDY DATA
Gender
 Male 23 (27%)
 Female 62 (73%)
Age (years)
 Mean ( ± SD) 76 ± 6
 >80 22 (12%)
Rhythm
 Sinus 72 (85%)
 AF 10 (11.5%)
 PM 3 (3.5%)
NYHA class
 I 6 (7%)
 II 37 (44%)
 III 24 (28%)
 IV 18 (21%)
Valvular lesion
 Pure or prevalent stenosis 79 (93%)
 Pure or prevalent incompetence 6 (7%)
Etiology
 Calcific degeneration 79 (82%)
 Valve prolapse 4 (5%)
 Rheumatic 2 (3%)
Prosthesis size
 21 mm 15 (18%)
 23 mm 43 (51%)
 25 mm 16 (19%)
 27 mm 3 (3%)
Associated procedures
 CABG 11 (13%)
 Ascending aorta replacement 1 (1%)
 Enlargement of aortic annulus 1(1%)
 Other 3 (3.5%)
AVR = aortic valve replacement; AF = atrial fibrillation; CABG = coronary artery 
bypass grafting; NYHA = New York Heart Association; PM = pacemaker.
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sutured in the supraannular position with 3 continuous su-
tures of 4/0 polypropylene (7-10). Care was always taken to 
avoid prosthesis distortion in the event of unequal sinuses 
of Valsalva (11). Associated surgical procedures were per-
formed in 17 patients (20%): of these, 11 patients had con-
comitant myocardial revascularization, 1 replacement of the 
ascending aorta, and 1 enlargement of the aortic annulus. 
Mean duration of cardiopulmonary bypass was 110 ± 26 
minutes and mean duration of aortic cross clamp time was 
89 ± 23 minutes. Prosthetic sizes implanted were as follows: 
21 mm in 15 patients (18%), 23 mm in 43 (51%), 25 mm in 
16 (19%), 27 mm in 8 (9%) and 29 mm in 3 (3%). 
Postoperative management
Following AVR, all patients were given subcutaneous hepa-
rin followed by oral anticoagulants on postoperative day 1 
or after extubation. Heparin was suspended when a target 
INR of 2.0 to 3.0 was reached. Oral anticoagulants were 
usually suspended after the first 3 postoperative months 
and replaced with antiplatelet drugs. Anticoagulation was 
maintained only in the presence of risk factors for thrombo-
embolic complications such as chronic AF. After discharge, 
all patients were entered in a follow-up program for heart 
valve recipients, which includes control visits at 1, 3, 6, and 
12 months, and yearly thereafter. A control transthoracic 2D 
echo-Doppler study was obtained at discharge and further 
controls then planned every 6 or 12 months. Clinical and 
echocardiographic follow-up aimed to verify patient status, 
occurrence of postoperative complications, and to assess 
SPF and LV performance. For patients who failed to come 
to the outpatient clinic, information was gathered from rela-
tives or referring physicians. Incidence and types of post-
operative complications were evaluated in compliance with 
recently revised guidelines (12). Follow-up ranged from 2 to 
135 months (mean follow-up of 78 ± 32 months) with a cu-
mulative duration of 6698 patient/years (pt/yrs). One patient 
could not be traced, yielding a 99% complete follow-up.
Statistical analysis
Data are presented as mean ± standard deviation and as 
simple percentages. Overall survival and freedom from valve-
related complications were determined by Kaplan-Meier 
actuarial analysis and expressed as percentage of patients 
who were event free ± standard error. The linearized rate of 
postoperative complications was expressed as %pt/yrs ± 
standard error. Student’s t test or Wilcoxon test for continu-
ous data and X2 or Fisher’s test for discrete variables were 
used, as appropriate. Statistical analyses were performed 
using SPSS version 16.0.1 (SPSS Inc, Chicago, IL, USA). 
RESULTS
Mortality and survival
There were 2 hospital deaths with a 2.4% mortality. One 
patient died of low output syndrome and multiorgan failure, 
and 1 of perioperative myocardial infarction. There were 35 
late deaths (42%) because of neoplasms in 13 patients, 
stroke in 4, senectus in 6, respiratory failure in 3, myocardial 
infarction in 2, endocarditis in 2, pulmonary embolism in 1, 
trauma in 1, bowel ischemia in 1, and rupture of an abdomi-
nal aneurysm in 1, while 1 died of unknown causes; 19 of 
the late deaths (54%) occurred in patients >80 years of age. 
Seven late deaths were considered to be valve-related with 
a linearized incidence of 0.10 ± 0.04 %pt/yrs; they were due 
to stroke in 4, endocarditis in 2 and unknown causes in 1. 
At 10 years actuarial survival is 45 ± 8% (Fig. 1) and actuarial 
freedom from valve-related deaths is 90 ± 4% (Fig. 2). Out of 
46 current survivors 40 (87%) are in NYHA class I or II, while 
5 are in class III with a mean NYHA class of 1.7 ± 0.7. 
Postoperative complications (Tab. II)
Thromboembolic episodes occurred in 5 patients with a 
linearized incidence of 0.07 ± 0.03 %pt/yrs; of these 4 were 
fatal while 1 patient sustained a major cerebral embolism. 
All embolic episodes occurred in patients >85 years of age; 
2 of them were on oral anticoagulants because of AF, 3 
were in sinus rhythm, but 1 of them had had a transient 
ischemic attack preoperatively. Actuarial freedom from 
thromboembolism is 92 ± 4% at 10 years (Fig. 3). 
Hemorrhagic complications were observed in 3 patients 
with an incidence of 0.04 ± 0.03 %pt/yrs. Two patients on 
anticoagulants because of AF had minor episodes treated 
medically; one had a hemorrhagic pericardial effusion after 
3 months requiring pericardial drainage; actuarial freedom 
from hemorrhages at 10 years is 96 ± 2%. 
Prosthetic endocarditis occurred in 4 patients, with an inci-
dence of 0.06 ± 0.03 %pt/yrs; 2 patients were successfully 
treated medically, 1 died at reoperation, and 1 died with-
out reoperation due to sepsis and cardiac failure. Actuarial 
freedom from endocarditis is 95 ± 2% at 10 years. 
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Structural deterioration of the SPF was observed in 2 pa-
tients, with a linearized incidence of 0.03 ± 0.02 %pt/yrs. 
An 82-year-old female was re-operated 6 years after AVR 
because of SPF incompetence due to a commissural tear 
with minimal calcification. A 74-year-old female was re-
operated after 5 years at another hospital because of SPF 
dysfunction; although details of the operative findings are 
not available, it is known that both patients survived reop-
eration. Actuarial freedom from structural valve deteriora-
tion is 96 ± 3% at 10 years (Fig. 4). 
Four patients required reoperation: 2 were reoperated due 
to structural valve deterioration, 1 due to endocarditis, and 
1 due to non-structural valve deterioration. All patients un-
derwent successful reoperation except the one with endo-
carditis. Actuarial freedom from reoperation is 93 ± 4% at 
10 years. 
Including late deaths, valve-related events occurred in 13 
patients: thromboembolism in 5, reoperation in 4, endo-
carditis in 3, and death for unknown causes in 1, with a 
linearized incidence of 0.19 ± 0.05 pt/yrs and an actuarial 
freedom at 10 years of 82 ± 5% (Fig. 2).
Echocardiographic data
At last follow-up, echocardiographic controls showed a 
PG of 18 ± 9 mm Hg, an MG of 9 ± 6 mm Hg, an effective 
Fig. 1 - Actuarial survival at 10 years. Fig. 2 - Actuarial freedom from valve-related mortality and valve-
related complications.
TABLE II - ACTUARIAL AND LINEARIZED RATES OF MAJOR POSTOPERATIVE COMPLICATIONS
Complication No. Linearized incidence
(%pt/yrs)
Actuarial freedom
% ± SE
5 years 10 years
Late deaths 35 - 76 ± 5 45 ± 8
Prosthesis-related deaths 7 0.10 ± 0.04 92 ± 3 90 ± 4
Thromboembolism 5 0.07 ± 0.03 96 ± 2 92 ± 4
- major 1 0.01 ± 0.01 - -
- fatal 4 0.06 ± 0.03 - -
Hemorrhages 3 0.04 ± 0.03 99 ± 1 96 ± 2
Endocarditis 4 0.06 ± 0.03 95 ± 2 95 ± 2
Structural failure 2 0.03 ± 0.02 100 96 ± 3
Reoperation 4 0.06 ± 0.03 97 ± 2 93 ± 4
Prosthesis-related complications 15 0.19 ± 0.05 86 ± 4 82 ± 5
%pt/yrs = Percent per patient years; SE = standard error.
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orifice area (EOA) of 1.88 ± 0.63 cm2, an indexed EOA of 
1.02 ± 0.47 cm2/m2, a LV mass index of 157 ± 43 gm/m2 
(p<0.001 when compared to preoperative values) and an 
LV ejection fraction of 56 ± 15%. Trivial aortic regurgitation 
was present in 15 patients (3 with a 21 mm SPF, 8 with a 
23 mm SPF, 3 with a 25 mm SPF and 1 with a 27 mm SPF) 
while moderate aortic regurgitation was found in 4 patients 
(3 with a 23 mm SPF and 1 with a 27 mm SPF). In terms 
of SPF sizes, echocardiographic data were available in 9 
patients with a 21 mm SPF, 33 with a 23 mm SPF, 9 with a 
25 mm SPF, and 6 with a 27 mm SPF (Tab. III). 
DISCUSSION
The SPF has been in clinical use for more than 2 decades 
(13). Despite this history, information of the long-term clinical 
performance of this device is extremely limited. Nagy et al 
reported the mid-term results of a series of 101 patients 
receiving an SPF with a maximum follow-up of 51 months 
(14). Grubitzsch and associates compared 50 patients with 
the SPF with 35 patients receiving another stentless valve 
with a maximum follow-up of 8 months (15). More recently, 
in a series of 102 patients, Nyawo et al reported an 89% sur-
vival, 96% freedom from thromboembolism and no instanc-
es of structural failures at 5 years (16). The only long-term 
follow-up study on the SPF is by D’Onofrio et al, who re-
ported their experience in 130 patients (10). At 7 years they 
Fig. 3 - Actuarial freedom from thromboembolic complications.
Fig. 4 - Actuarial freedom from structural valve deterioration (SVD).
TABLE III - ECHOCARDIOGRAPHIC DATA
21 mm 23 mm 25 mm 27 mm
PRE
OPERATIVE 
POST
OPERATIVE 
PRE
OPERATIVE 
POST
OPERATIVE 
PRE
OPERATIVE 
POST
OPERATIVE 
PRE
OPERATIVE 
POST
OPERATIVE 
LVEF (%) 64 ± 10 60 ± 8 58 ± 11 56 ± 12 61 ± 11 58 ± 10 55 ± 11 52 ± 14
Aortic PG (mm Hg) 94 ± 17 20 ± 10* 82 ± 18 19 ± 10* 84 ± 34 16 ± 8* 83 ± 31 11 ± 6*
Aortic MG (mm Hg) 63 ± 14 11 ± 7* 54 ± 14 10 ± 6* 55 ± 24 8 ± 6* 56 ± 27 8 ± 6*
EOAi (cm2/m2) 0.34 ± 0.10 0.94 ± 0.12* 0.37 ± 0.13 1.11 ± 0.25* 0.55 ± 0.26 1.20 ± 0.28* 0.41 ± 0.24 1.25 ± 0.20*
LVMI (g/m2) 225 ± 42 191 ± 32* 209 ± 34 158 ± 27* 206 ± 49 135 ± 37* 208 ± 48 126 ± 26*
LVFE = left ventricular ejection fraction; Aortic PG = aortic peak gradient; Aortic MG = aortic mean gradient; EOAi = effective orifice area indexed; LVMI = left ventri-
cular mass index ; * = p<0.001 pre-operative vs. post-operative values.
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reduction of LV hypertrophy is demonstrated over time. 
Interestingly, hemodynamic performance of the SPF does 
not seem to be influenced by different implantation tech-
niques (8, 14).
Recently, Sorin Biomedica began manufacturing another 
pericardial stentless valve, the Freedom Solo, which is di-
rectly derived from the SPF. The Fredom Solo has the same 
manufacturing process and tissue treatment, but differs 
from the SPF in that the external pericardial support has 
been eliminated, allowing it to be implanted with a single 
suture line in complete supra-annular position. Early clini-
cal and hemodynamic results with the Solo stentless valve 
are gratifying but long-term data are not currently avail-
able (25). Particularly owing to its ease of implantability, the 
Solo valve will probably render the SPF obsolete in a short 
time. However, we believe that continuous and extended 
follow-up information on the SPF may be helpful to verify 
durability of this new device. 
The Freedom Solo bioprosthesis has been associated 
with the occurrence of postoperative thrombocytopenia 
in recent reports (26-28). This problem has never been 
investigated in patients with an SPF (10, 14-16). Due to 
the retrospective nature of this paper we were unable to 
verify occurrence of platelet count reduction in all our 
patients. In a small subset, too limited to gain statisti-
cal significance, however, we were able to confirm that 
postoperative thrombocytopenia is present in SPF pa-
tients, with a behavior similar to that in patients with the 
Freedom Solo bioprosthesis (27). Reduction of platelets, 
to values <150,000/µl, occurs on the first postoperative 
day, continues throughout the postoperative period, and 
does not completely normalize at discharge. These ob-
servations seem to support the theory that the peculiar 
tissue treatment of the Solo and the SPF might play an 
important role in causing thrombocytopenia after AVR 
(26, 28).
The major limitations of our study are its retrospective 
design and the limited number of patients. Echocardio-
graphic evaluation of LV mass in retrospective studies may 
be another limitation, since analysis is performed by differ-
ent operators. Nevertheless, we believe that an accurate 
follow-up, which was 99% complete, has provided mean-
ingful data for assessing the long-term performance of the 
SPF. Furthermore, we are also confident that the informa-
tion provided by this study can be used as a valid reference 
point for comparison with the new generation of pericardial 
stentless devices used for AVR, either with standard tech-
observed a 50% survival, 94% freedom from reoperation 
and 91% freedom from valve-related deaths. In addition, no 
cases of structural valve deterioration were observed in their 
study. Our paper thus appears to be the first long-term re-
port on the clinical performance of the SPF with a maximum 
follow-up of over 11 years. Our results confirm the overall 
good performance of the SPF, particularly in terms of free-
dom from valve-related complications. In this respect, the 
safety of the SPF can also be confirmed by comparison with 
the rate of valve-related complications reported with other 
stentless and stented bioprostheses (5, 17-19). However, 
it is difficult to compare our results with those of previous 
reports due to the differences in follow-up intervals. Patient 
survival in our series was similar to that reported by others 
at 7 years (10). The high mean age of our patients at time of 
AVR and the fact that over 50% of late deaths occurred in 
patients 80 years of age or older must be stressed. 
There were 5 major thromboembolic episodes, all occur-
ring in patients >85 years of age; however, considering 
the possibility of concomitant cerebral vascular disease 
in this very old patient subset, these episodes might have 
been overestimated since some of the cerebral ischemic 
events were probably not strictly valve-related. No cas-
es of SPF structural valve deterioration have been so far 
reported in short- and medium-term studies (10, 14-16). 
Only one case of SPF failure had been documented previ-
ously (20): an 84-year-old female underwent replacement 
of a severely calcified SPF 6 years after AVR. At reopera-
tion, excision of the SPF cusps left a rigid and diminutive 
aortic annulus which required an annular enlargement pro-
cedure to insert a prosthesis of adequate size (20). In the 
present series 2 patients underwent reoperation because 
of SPF failure. In 1 of them, severe valve incompetence 
was caused by a commissural tear with mild calcification, 
while in the other, operative details are lacking since reop-
eration was performed at another hospital. These results 
seem to confirm that durability of the SPF is satisfactory at 
10 years; however, they also indicate that occasionally the 
SPF can undergo structural changes with a failure mode 
similar to that reported with traditional porcine or pericar-
dial bioprostheses (21-23). 
The SPF has demonstrated excellent hemodynamic per-
formance in our experience as well, confirming results re-
ported by others (7, 8, 10, 24). In our series low gradients 
and large valvular areas were recorded even in the small 
sizes. The hemodynamic benefit of the SFS is particularly 
evident in patients with aortic stenosis in whom significant 
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less prosthesis: 7 years’ experience in 130 patients. J 
Thorac Cardiovasc Surg. 2007;134(2):491-495. 
11. Beholz S, Konertz WF. Avoiding early partial valve throm-
bosis of the Pericarbon Freedom stentless valve. J Heart 
Valve Dis. 2007;16(1):91-92.
12. Akins CW, Miller DC, Turina MI, et al. Guidelines for re-
porting mortality and morbidity after cardiac valve inter-
ventions. J Thorac Cardiovasc Surg. 2008;135(4):732-
738. 
13. Repossini A, Kotelnikov I, Bouchikhi R, et al. Single-
suture line placement of a pericardial stentless valve. J 
Thorac Cardiovasc Surg. 2005;130(5):1265-1269. 
14. Nagy ZL, Bodi A, Len A, Balogh I, Peterffy A. Three years’ 
experience with the Sorin Pericarbon stentless prosthe-
sis: mid-term results with three different implantation 
techniques. J Heart Valve Dis. 2005;14(1):72-77.
15. Grubitzsch H, Linneweber J, Kossagk C, Sanli E, Beholz 
S, Konertz WF. Aortic valve replacement with new-gener-
ation stentless pericardial valves: short-term clinical and 
hemodynamic results. J Heart Valve Dis. 2005;14(5):623-
629.
16. Nyawo B, Graham R, Hunter S. Aortic valve replacement 
with the Sorin Pericarbon Freedom stentless valve: five-
year follow-up. J Heart Valve Dis. 2007;16(1):42-48.
17. Yankah C, Pasic M, Musci M, et al. Aortic valve replace-
ment with the Mitroflow pericardial bioprosthesis. J Thorac 
Cardiovasc Surg. 2008;136(3):688-696. 
18. Mykén PS, Bech-Hansen O. A 20-year experience of 
1712 patients with the Biocor porcine bioprosthesis. J 
Thorac Cardiovasc Surg. 2009;137(1):76-81. 
19. Valfrè C, Ius P, Minniti G, et al. The fate of Hancock II por-
cine valve recipients 25 years after implant. Eur J Cardio-
thorac Surg. 2010;38(2):141-146. 
20. Croccia MG, Pratali S, Basso C, et al. Early calcification 
of a stentless pericardial bioprosthesis in the elderly. J 
Thorac Cardiovasc Surg. 2009;137(5):1273-1275. 
21. Milano A, Bortolotti U, Talenti E, et al. Calcific degen-
niques or through transfemoral or transapical approaches.
In conclusion, a 10-year follow-up of patients receiving an 
SPF indicates that this bioprosthesis has satisfactory clini-
cal results with an overall low rate of major complications. 
Based on its excellent hemodynamic performance, we can 
confirm that the SPF may be especially indicated in elderly 
patients requiring AVR for severe aortic stenosis.
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